ROYALTIES TO LICENSOR Sample Clauses

ROYALTIES TO LICENSOR. Royalties to Licensor will be due and payable according to the following terms.
Sample 1Sample 2
AutoNDA by SimpleDocs
ROYALTIES TO LICENSOR. 5.1 [redacted]
Sample 1
ROYALTIES TO LICENSOR. 5.1 Licensee shall pay to Licensor by wire transfer, within ten (10) days after the signing of this Agreement, as an advance royalty payment, the amount of $100,000. The initial royalty payment shall be non-refundable and shall be credited solely against the first year minimum royalty payment as set forth herein.
Sample 1
ROYALTIES TO LICENSOR. 5.1 Royalties due to Licensor by Licensee for the sale of Goods shall be calculated based upon the classification of the Goods into two product categories: (1) voice activated products and (2) core products. Voice activated products shall be all Goods which are activated utilizing a voice recognition feature and do not require manual activation, and core products shall be all Goods which are not voice activated products.
Sample 1
ROYALTIES TO LICENSOR. Ventrus shall pay to Licensor the following royalties on Annual Net Sales of each Ventrus Product and Ventrus Therapy on a worldwide basis provided such Ventrus Product or Ventrus Therapy is Covered by a Valid Claim of a Licensor Patent: Amount Royalty Rate/Payment Annual Net Sales of applicable Product or Therapy on sales of less than $[*] million [*]% of such Net Sales Annual Net Sales of applicable Product or Therapy on sales of $[*] million or more [*]% of such Net Sales If Annual Net Sales of applicable Product or Therapy are between $[*] million and less than $[*] million $[*] million one-time payment with respect the applicable Product or Therapy (in addition to any other of Ventrus’s royalty obligations or payments) If Annual Net Sales Of applicable Product or Therapy are $[*] million or more $[*] million one-time payment with respect the applicable Product or Therapy (in addition to any other Ventrus’s royalty obligations or payments) [*] Confidential treatment requested; certain information omitted and filed separately with the SEC.
Sample 1
ROYALTIES TO LICENSOR. (a) Licensee shall pay to Licensor for each Licensed Product licensed to a Redistributor or a Customer a royalty equal to the Specified Royalty Percentage of all revenues received (without deduction for value added tax, if any, but excluding any revenues for maintenance and support or upgrade services, which revenues are covered in paragraph (b) below) by Licensee under the Redistributor Agreement or Sublicense applicable to such Licensed Product.
Sample 1
ROYALTIES TO LICENSOR. 5.1 Licensee shall pay to Licensor, as an advance royalty payment, the amount of $50,000. Licensee shall pay the advance royalty payment either by immediately available funds within five (5) days following the Effective Date or by opening an irrevocable standby letter of credit in favor of Licensor on the Effective Date, with a bank reasonably satisfactory to Licensor and that maintains a confirmation relationship with Licensor's bank, in the amount of $50,000, payable within five (5) days. The advance royalty payment shall be non- refundable and shall be credited against the Minimum Royalty Fee as set forth herein so that no Royalty Fees as defined herein shall be payable by Licensee until Licensee's advance royalty credit is reduced to zero.
Sample 1
AutoNDA by SimpleDocs

Related to ROYALTIES TO LICENSOR

  • Licensee Licensee represents and warrants that:

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Research License Following Selection of each CGI Antigen (or exercise of a Buy-In Right for each CGI Antigen) and subject to the terms and conditions of this Agreement, ABX agrees to grant, and hereby grants, to CGI a nonexclusive sublicense under the Licensed Technology to develop, make, have made, use, import or export or otherwise transfer physical possession of (but not to sell, lease, offer to sell or lease, or otherwise transfer title to) Covered Products related to such CGI Antigen and cells that express or secrete Antibodies to such CGI Antigen, in each case solely for purposes relating to or in connection with research or development (i) of Covered Products for use in the field of Gene Therapy or (ii) involving Genetic Material when used with viral or nonviral gene transfer systems. CGI shall have the right to sublicense the rights granted under this Section 2.5 upon the approval of ABX, which approval shall not be unreasonably withheld. In the event that ABX refuses to approve such a sublicense, ABX shall, to the extent that ABX has the right to do so, grant at CGI's request a nonexclusive sublicense of such rights directly to a non-Affiliate third party designated by CGI on terms and conditions substantially identical to the applicable terms and conditions of this Agreement. The sublicense granted by ABX under this Section 2.5 with respect to a CGI Antigen (and the further sublicenses, if any, granted by CGI under this Section 2.5 with respect to such CGI Antigen) shall terminate at such time as (A) CGI sends ABX an Abandonment Notice pursuant to Section 2.4.1 above regarding such CGI Antigen or (B) CGI enters into a CGI Product Sublicense related to such CGI Antigen; provided, however, that termination of a sublicense under this Section 2.5 with respect to a CGI Antigen pursuant to (B) above shall not affect the duration or survival of a grant of similar rights or sublicense under the CGI Product Sublicense with respect to such CGI Antigen, which rights or sublicense shall terminate or expire only in accordance with the terms of such CGI Product Sublicense. In the event that ABX enters into a Product Sublicense with respect to a CGI Antigen and CGI has not within six (6) months thereafter entered into a CGI Product Sublicense with respect to such CGI Antigen, the sublicense granted under this Section 2.5 with respect to such CGI Antigen shall terminate. It is understood and agreed that (x) as to ABX-Controlled Rights, the grant of rights under this Section 2.5 shall be subject to and limited in all respects by the terms of the applicable ABX In-License(s) pursuant to which such ABX-Controlled Rights were granted to ABX and (y) the rights and sublicenses granted to CGI under this Section 2.5 or any other provision of this Agreement shall be subject in all respects to the GenPharm Cross License.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Licensor any Person from whom a Grantor obtains the right to use any Intellectual Property. Lien: any Person’s interest in Property securing an obligation owed to, or a claim by, such Person, whether such interest is based on common law, statute or contract, including liens, security interests, pledges, hypothecations, statutory trusts, reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting Property. Lien Waiver: an agreement, in form and substance satisfactory to Collateral Agent, by which (a) for any material Collateral located on leased premises, the lessor waives or subordinates any Lien it may have on the Collateral, and agrees to permit Collateral Agent to enter upon the premises and remove the Collateral or to use the premises to store or dispose of the Collateral; (b) for any Collateral held by a warehouseman, processor, shipper, customs broker or freight forwarder, such Person waives or subordinates any Lien it may have on the Collateral, agrees to hold any Documents in its possession relating to the Collateral as agent for Collateral Agent, and agrees to deliver the Collateral to Collateral Agent upon request; (c) for any Collateral held by a repairman, mechanic or bailee, such Person acknowledges Collateral Agent’s Lien, waives or subordinates any Lien it may have on the Collateral, and agrees to deliver the Collateral to Collateral Agent upon request; and (d) for any Collateral subject to a Licensor’s Intellectual Property rights, the Licensor grants to Collateral Agent the right, vis-à-vis such Licensor, to enforce Collateral Agent’s Liens with respect to the Collateral, including the right to dispose of it with the benefit of the Intellectual Property, whether or not a default exists under any applicable License.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Royalties 8.1 In consideration of the license herein granted, LICENSEE shall pay royalties to LICENSOR as follows:

  • Sublicense (a) The license granted in Paragraph 2.1 includes the right of LICENSEE to grant Sublicenses to third parties during the Term but only for as long as the license to Patent Rights is exclusive.

  • Royalty 8.1 In consideration of the rights granted under clause 2, the Licensee shall pay to the Licensor royalties, on each twelve month time period, first calculated from the date of execution of this Agreement, and calculated on a scale as follows:

  • Third Party Royalties Each party shall be responsible for all of its own costs of commercializing Products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sublicensees.

Time is Money Join Law Insider Premium to draft better contracts faster.